FDA approves Eylea for all forms of macular edema after retinal vein occlusion

Article

The U.S. Food and Drug Administration (FDA) recently approved Eylea (afilbercept, Regeneron) for all forms of macular edema after retinal vein occlusion, including branch retinal vein occlusion.

Tarrytown, NY-The U.S. Food and Drug Administration (FDA) recently approved Eylea(afilbercept, Regeneron) for all forms of macular edema after retinal vein occlusion, including branch retinal vein occlusion.

The drug is also approved for macular edema after central retinal vein occlusion, as well as wet age-related macular degeneration, and visual impairment caused by DME.

The FDA based its decision to expand aflibercept's indication on the prior indication for macular edema after CRVO and a clinical trial that compared the drug with macular laser photocoagulation in 181 patients with BRVO, according to Regeneron. After 24 weeks, 53 percent of patients treated with aflibercept gained at least 15 letters in vision from baseline on an eye chart compared with 27 percent of those undergoing the laser procedure. Tested for best-corrected visual acuity, patients receiving aflibercept experienced a mean improvement of 17 letters compared with a 6.9-letter gain for the other patients.

A recent National Institutes of Health-sponsored study found Eylea injection demonstrated the most improvement in best-corrected visual acuity (BCVA) from baseline at 52 weeks in patients with diabetic macular edema (DME) when compared to Avastin (bevacizumab, Genentech) and Lucentis (ranibizumab, Genentech) injection.

The study was designed to determine if one of three different anti-VEGF therapies is superior to the others for the treatment of DME. In the study, 660 patients were randomized to receive either Eylea 2 milligrams (mg), Avastin 1.25 mg, or Lucentis 0.3 mg dosed according to a protocol-specified algorithm.

Study: using Avastin instead of Lucentis to treat AMD, DME could save Medicare billions

The median number of injections using the protocol-specific retreatment regimen was one fewer in the patients treated with Eylea compared to Lucenis and Avastin. And fewer patients received criteria-based macular laser treatments in the Eylea group than the other groups.

The rates of most ocular and systemic adverse events were similar across the three study groups. The rates of arterial thromboembolic events were two percent in the Eylea group, four percent in the Avastin group, and five percent in the

Lucentis group. There were more overall cardiovascular events in the Lucentis group, compared to the Eylea group and the Avastin group, which included more cardiac events and cerebrovascular events in the Lucentis group.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Carolyn Majcher, OD, FAAO, detailed a talk she gave alongside Mary Beth Yackey, OD, at Optometry's Meeting 2025.
Alongside Rachel Steele, OD, Rafieetary outlines what to look for in blurred disc margins and the importance of acting fast and sending patients to the ED when needed.
Rachelle Lin, OD, MS, FAAO, on collaborating more effectively on neovascular retinal cases
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
CIME 25: Dilsher Dhoot, MD, FASRS, is excited about emerging retinal therapies.
Steven Ferrucci, OD, FAAO, at Controversies in Modern Eyecare 2025
CRU 2025 provided the latest insights regarding glaucoma, dry eye disease, retina, myopia, neurotrophic keratitis, and keratoconus.
Rachelle Lin, OD, MS, FAAO
Rachelle Lin, OD, MS, FAAO, at CRU Eye Symposium 2025
Rachelle Lin, OD, MS, FAAO, details her presentation on inherited retinal diseases at CRU 2025.
© 2025 MJH Life Sciences

All rights reserved.